ive dyspnea on exertion (DOE), a nonproductive cough ± fever, restrictive changes in pulmonary function and occasional radiographic infiltrates. 2 The optimal approach Drug-induced pulmonary toxicity is one of the most frequent non-hematologic toxicities in breast cancer to diagnosis and treatment, however, has not been elucidated. patients receiving high-dose chemotherapy with cyclophosphamide, cisplatin and BCNU (CY/CDDP/BCNU).
Pulmonary evaluation Results

Pretreatment evaluation included a history and physical
Clinical features examination, chest radiograph (PA and lateral), spirometry with DLCO (single breath diffusion capacity with standard Sixty-four consecutive female patients were studied. The patient characteristics are shown in Table 1 . The median Coles hemoglobin correction) and a 2-min flat walk oximeage of the patients was 45 years and the majority (61%) try. Following hospital discharge, patients were routinely were treated for high-risk breast disease. Six of the patients followed-up at 1 and 2 weeks, monthly for 3 months and had pulmonary metastases; none of these demonstrated a every 2 months thereafter. Evaluation consisted of a symplymphangitic pattern of disease. The majority of the tom history, physical examination and laboratory studies, patients received radiation to the chest wall and regional including a complete blood count and chemistry panel.
lymph nodes following transplantation. Only eight of the Patients who reported symptoms suggestive of possible pulpatients had a smoking history, and one patient had a hismonary toxicity (eg DOE, cough, fever or chest tightness) tory of sarcoidosis which was quiescent at the time of transunderwent additional testing with DLCO, 2-min walking plantation. oximetry and a chest radiograph. In nearly all instances, Treatment was instituted in 37 patients (58%) who the DLCOs and oximetry were done on the same machine developed clinical evidence of pulmonary toxicity. Thirty and evaluated by the same technician. Patients who lived of these patients (81%) had a complete pulmonary evalutoo far away to travel to the transplant center for a full ation, as described above, and were assigned a clinically pulmonary evaluation were encouraged to see their primary weighted score. Twenty-six of the 30 patients (87%) had a physicians and maintain contact by phone. All patients were clinical diagnostic score of у6, one had a score of 5 and followed for their response to treatment and outcome. A three had a score of 3 with symptoms (DOE) and a marked therapeutic response to treatment was defined as the resoldecrease from their baseline DLCOs (−30, −31 and −50%). ution of pulmonary symptoms and normalization of pulAlthough the latter three patients did not meet the diagnosmonary function tests. The median follow-up was 28 tic criteria, they were treated on the basis of significant months (range, 22-34 months) post-transplantation.
DOE and decrease in DLCO. The remaining seven patients were treated empirically, five based on symptoms, alone and two based on symptoms and a decreased DLCO. The clinical features of the patients who were treated are Diagnosis and treatment summarized in Table 2 . The median onset of pulmonary toxicity was 56 days (range, 21-240 days) from day 0 of A clinically weighted point scoring system was developed transplantation. The most common symptom reported by to serve as a model for the diagnosis of pulmonary toxicity:
affected patients was the subacute development of dyspnea crackles on lung exam, 2; decrease in corrected DLCO by on exertion (30 patients (81%) ), usually evolving over sev-Ͼ10% from baseline, 3; decrease in O 2 saturation by у4% eral days. Eight patients (22%) reported having a dry with a 2-min walk, 3; and interstitial infiltrates on chest cough, six as an isolated symptom, and three patients radiograph, 3. The individual scores assigned to these parareported a fever Ͼ38.0°C, one as an isolated symptom and meters were based on the authors' previous experience in two in conjunction with DOE. identifying this syndrome. Patients with a score у6 were Physical examination was abnormal in only three (8%) treated with prednisone; scores Ͻ6 were followed up of the patients. Two patients had bibasilar inspiratory weekly until stable over 6 weeks or treatment criteria were crackles and one had diffuse, end-expiratory wheezing. met. Prednisone therapy was instituted at a dose of 60 mg p.o. twice a day for 10 days, followed by 30 mg q day × 1 week, 20 mg q day × 1 week, 15 mg q day × 1 week and then tapered by 5 mg once a day, each week thereafter. One patient received XRT to the spine only. cystis carinii pneumonia (PCP) which responded to i.v.
Median decrease 6
trimethoprim/sulfamethoxazole and the other three had Chest X-ray (n = 30) (%)
non-diagnostic findings. Two of the latter patients ultiAbnormal 13 (43) mately recovered and the third patient was found to have lymphangitic spread of carcinoma on open lung biopsy. Four of the 37 patients expired, two from progressive metaPulmonary function tests static, visceral disease (2 and 7 months following transplantation), one from carcinomatous meningitis (at 4. Thirty-two of the treated patients were evaluated with a months), and another from cytomegalovirus (CMV) pneucorrected DLCO, of which 30 experienced Ͼ10% decrease monitis (at 3 months). The remaining patients were treated from their pretransplant level, with a median decrease of with prednisone for 2-3 months. At a median follow-up of 27% from baseline. Twenty-eight of these patients also 28 months, the majority of patients report full recovery with underwent 2-min exercise oximetry, of which 19 had a a few continuing to have mild DOE. No patient has decrease in oxygen saturation of Ͼ4% with a median developed evidence of progressive pulmonary disease due decrease of 6%. Only two of the patients diagnosed with to drug toxicity. pulmonary toxicity had a Ͼ4% decrease in oximetry without a concomitant fall in DLCO. In contrast, four of the patients had a fall in DLCO of Ͼ10% without a significant
Comparisons with untreated patients decline in oximetry.
Differences in disease status (locally advanced vs metastatic), radiation treatment or history of tobacco use Radiographic studies were not associated with significant differences in the proportion of patients who met criteria for the diagnosis of Of the 37 patients who developed clinical evidence of pulpulmonary toxicity (Table 3 ). No differences in the rate of monary toxicity, 30 had a chest X-ray examination; 13 of these were abnormal. The most comon finding was bilateral Table 3 Characteristics of patients with and without pulmonary interstitial infiltrates, in 9/13 studies, followed by unilateral litis typical of drug toxicity. Three of these patients also had chest X-rays which revealed interstitial infiltrates; the Age (years) remaining patient's chest X-ray was within normal limits. already completed a course of prednisone therapy; only one of these patients required prednisone treatment beyond 2 pulmonary toxicity were observed in patients receiving Gdrug-induced lung toxicity and chose to use these tests in our predictive model. A significant decline (Ͼ10%) in cor-CSF as compared to G-CSF + SCF for PBPC mobilization. A higher proportion of patients р50 years than those over rected DLCO from baseline, as weighted by our scoring system, appeared to be the most sensitive predictor of pul-50 years of age met criteria for the development of lung toxicity (68% vs 35%, P = 0.01). There was no apparent monary toxicity. The 2-min exercise oximetry was also abnormal in the majority of treated patients, but was only coexisting variable, such as number of previous therapies, to account for the increased incidence of toxicity in rarely abnormal in the setting of a normal DLCO. Less than 50% of the patients had abnormal radiographs younger patients.
and one patient was found to have an abnormal highresolution computerized tomography (HRCT) with a normal radiograph. HRCT has been demonstrated to be more Discussion sensitive than radiographs in the diagnosis of chemotherapy-induced lung disease, with the most frequent In this study, we used a clinical point scoring system as a non-invasive tool to diagnose chemotherapy-associated appearance on HRCT being fibrosis, with or without consolidation, or patchy, ground-glass opacification.
7 pulmonary toxicity in breast cancer patients treated with high-dose CY/CDDP/BCNU. Ninety per cent of the Pre-or post-transplant radiation did not predict for the development of pulmonary toxicity. However, patients patients were diagnosed on the basis of these criteria and treated with prednisone. The remaining patients were diagreceiving XRT were more likely to demonstrate a protracted course and a slower response to steroid treatment; nosed and treated on the basis of DOE ± a decrease in DLCO. None of the patients in the study developed proattempts at withdrawing steroids during radiation often resulted in a flare of symptoms. We recommend that stergressive lung disease. The 58% incidence observed in this series of patients is higher than that reported by other oids be tapered with caution and/or be continued until the XRT is completed. For patients diagnosed with pulmonary authors 4, 5 and may be explained by one or more variables. Todd et al 4 required new radiographic opacities for diagtoxicity prior to the onset of radiation, consideration should be given to delaying radiation until prednisone has been nosis whereas in our study, only 43% of the treated patients had radiographic abnormalities. The patients with normal discontinued. In our series, a higher rate of pulmonary toxicity was observed in patients under 50 years of age. This radiographs may have been diagnosed at an earlier stage of pulmonary toxicity, with the development of symptoms and has not been reported previously and merits examination in future studies of this complication. a decline in DLCO and oximetry preceding the development of frank pulmonary infiltrates. This is supported by None of the patients in this series were diagnosed on the basis of invasive testing. Open lung biopsy findings for this the absence of progression to pulmonary fibrosis in any of the patients. In contrast, Todd et al diagnosed 23 patients syndrome are non-specific but consistent with drug toxicity, with an increase in type II pneumocytes, vascular injury, with pulmonary toxicity, 10 of whom underwent open lung biopsy. Three of these patients died 2-6 months following increased alveolar macrophages and hyaline membrane formation with diffuse alveolar damage. 4 chemotherapy from severe drug-induced lung toxicity. Many of their patients also required high doses of supThe process by which high-dose chemotherapy results in pulmonary toxicity is unknown. Both cyclophosphamide plemental oxygen. Another confounding variable is that five of our patients were treated empirically, based only on and BCNU are known to cause lung toxicity and when used together, may have an adverse synergistic effect. In a dosethe development of DOE, without formal pulmonary testing. If these patients are excluded from the analysis, howescalation study of BCNU, a 24% incidence of interstitial pneumonitis with a 9.5% mortality rate was observed at a ever, the incidence of pulmonary toxicity only decreases to 54% (32/59). Although other diagnoses might have met the dose of 1200 mg/m 2 . 6 Other studies have reported a 20-30% incidence of pulmonary toxicity in patients treated proposed diagnostic criteria for pulmonary toxicity, it is unlikely amongst our clinical cohort of patients. It is with BCNU for gliomas. 8, 9 The incidence appears to be less at lower doses but may be enhanced when used with highimprobable that any of these patients had occult pulmonary hemorrhage, given the delayed and subacute onset of sympdose cyclophosphamide. 10 Pulmonary toxicity associated with cyclophosphamide has not been as well documented toms, as well as hematologic recovery; the lack of disease progression on steroids makes CMV pneumonitis or other by clinical studies but is supported by reports in humans as well as animals.
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infectious processes unlikely; and clinically, none of the patients presented with evidence of congestive heart failure. The underlying mechanism(s) by which these drugs cause adverse pulmonary reactions remains to be fully The clinical presentation of these patients was most notable for the subacute development of dyspnea on exerelucidated. The proposed mechanism for carmustine pulmonary damage is through decreased availability of tion with the physical examination only rarely being helpful. The median onset of symptoms was 56 days following reduced glutathione (GSH) by the inhibition of glutathione reductase. 12 GSH is an important antioxidant defense mechstem cell infusion but occurred as late as 240 days. With regard to non-invasive pulmonary testing, primarily restricanism of lung tisue. Cyclophosphamide also depletes GSH stores through direct binding with its metabolite, acrolein, 13 tive lung changes with no evidence of obstruction have been documented by some authors, 4, 6 whereas others have and has been shown to increase oxidant production by macrophages in rats treated with the drug. 14 Thus, the pulalso observed a significant decline in FEV1.
5 Based on our own prior experience, we found DLCO and exercise oximemonary toxicity observed in patients treated with BCNU and cyclophosphamide may be the result of a combined try to be the most sensitive pulmonary function tests for dose chemotherapy with autologous stem cell support for
